<!DOCTYPE html>
<html lang="en" dir="ltr">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Dystonia DYT1 Hub | CarePedia Information Center</title>
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Rubik:wght@300;400;500;600;700;800;900&display=swap" rel="stylesheet">
<link rel="alternate" hreflang="he" href="https://carepedia.org/dystonia" />
<link rel="alternate" hreflang="en" href="https://carepedia.org/en/dystonia" />

<style>
* { margin: 0; padding: 0; box-sizing: border-box; }

:root {
  --primary: #0f4c75;
  --primary-light: #3282b8;
  --accent: #00b894;
  --accent-light: #55efc4;
  --warm: #fdcb6e;
  --warm-dark: #e17055;
  --bg: #f0f4f8;
  --card: #ffffff;
  --text: #2c3e50;
  --text-light: #5d6d7e;
  --shadow: 0 4px 20px rgba(0,0,0,0.08);
  --shadow-hover: 0 12px 40px rgba(0,0,0,0.18);
  --radius: 16px;
  --transition: all 0.3s cubic-bezier(.4,0,.2,1);
  /* Aliases for Iconify icons */
  --forest: #0f4c75;
  --forest-mid: #3282b8;
  --forest-light: rgba(50,130,184,0.12);
  --amber: #fdcb6e;
  --amber-light: rgba(253,203,110,0.12);
  --border: #dde4eb;
}

body {
  font-family: 'Rubik', 'Segoe UI', Tahoma, Arial, sans-serif;
  background: var(--bg);
  color: var(--text);
  line-height: 1.8;
  overflow-x: hidden;
  position: relative;
}

body::before {
  content: '';
  position: fixed;
  top: 0; left: 0; width: 100vw; height: 100vh;
  background:
    radial-gradient(ellipse at 10% 20%, rgba(15,76,117,0.07) 0%, transparent 50%),
    radial-gradient(ellipse at 90% 80%, rgba(0,184,148,0.07) 0%, transparent 50%),
    radial-gradient(ellipse at 50% 50%, rgba(253,203,110,0.05) 0%, transparent 60%);
  pointer-events: none;
  z-index: 0;
}

.scroll-progress {
  position: fixed;
  top: 0; right: 0;
  width: 100%; height: 4px;
  z-index: 2000;
  background: transparent;
}
.scroll-progress .bar {
  height: 100%; width: 0%;
  background: linear-gradient(90deg, var(--accent), var(--primary-light), var(--warm));
  border-radius: 0 0 0 4px;
  transition: width 0.1s linear;
}

.sidebar {
  position: fixed;
  top: 0; left: 0;
  width: 280px; height: 100vh;
  background: rgba(15,76,117,0.85);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border-right: 1px solid rgba(255,255,255,0.1);
  z-index: 1000;
  padding: 30px 20px;
  overflow-y: auto;
  transition: transform 0.4s cubic-bezier(.4,0,.2,1);
}
.sidebar .logo {
  text-align: center;
  margin-bottom: 30px;
  padding-bottom: 20px;
  border-bottom: 1px solid rgba(255,255,255,0.15);
}
.sidebar .logo .icon { font-size: 48px; }
.sidebar .logo h2 { color: #fff; font-size: 18px; margin-top: 8px; font-weight: 600; }
.sidebar nav a {
  display: flex; align-items: center; gap: 12px;
  padding: 14px 18px; color: rgba(255,255,255,0.8);
  text-decoration: none; border-radius: 12px;
  margin-bottom: 4px; font-size: 15px; transition: var(--transition);
}
.sidebar nav a:hover, .sidebar nav a.active {
  background: rgba(255,255,255,0.15); color: #fff; transform: translateX(4px);
}
.sidebar nav a .nav-icon { font-size: 22px; min-width: 30px; text-align: center; }

.menu-toggle {
  display: none;
  position: fixed;
  top: 20px; left: 20px;
  z-index: 1100;
  background: var(--primary); color: #fff;
  border: none; border-radius: 12px;
  width: 50px; height: 50px; font-size: 24px;
  cursor: pointer; box-shadow: var(--shadow); transition: var(--transition);
}
.menu-toggle:hover { transform: scale(1.05); }
.menu-toggle.open { border-radius: 50%; background: var(--warm-dark); }

.main {
  margin-left: 280px;
  min-height: 100vh;
  position: relative;
  z-index: 1;
}

.hero {
  background: linear-gradient(135deg, var(--primary) 0%, #3282b8 40%, var(--accent) 100%);
  padding: 80px 60px;
  color: #fff;
  position: relative;
  overflow: hidden;
}
.hero::before {
  content: '';
  position: absolute;
  top: -50%; left: -50%;
  width: 200%; height: 200%;
  background: radial-gradient(circle, rgba(255,255,255,0.05) 0%, transparent 60%);
  animation: float 20s linear infinite;
}
@keyframes float { 0% { transform: rotate(0deg); } 100% { transform: rotate(360deg); } }
.hero-content { position: relative; z-index: 1; max-width: 900px; }
.hero h1 { font-size: 52px; font-weight: 800; margin-bottom: 10px; line-height: 1.3; }
.hero .greeting { font-size: 22px; opacity: 0.95; margin-bottom: 30px; line-height: 1.7; }
.hero .subtitle { font-size: 18px; opacity: 0.8; max-width: 700px; }

.fade-in { opacity: 0; transform: translateY(30px); transition: opacity 0.7s ease, transform 0.7s ease; }
.fade-in.visible { opacity: 1; transform: translateY(0); }

.section { padding: 60px; max-width: 1100px; margin: 0 auto; }
.section-header {
  display: flex; align-items: center; gap: 16px;
  margin-bottom: 40px; padding-bottom: 20px;
  border-bottom: 3px solid var(--primary-light);
}
.section-header .sec-icon { font-size: 42px; }
.section-header h2 { font-size: 36px; color: var(--primary); }
.section-header p { color: var(--text-light); font-size: 16px; margin-top: 4px; }

.cards-grid {
  display: grid;
  grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
  gap: 24px; margin-bottom: 40px;
}
.card {
  background: var(--card); border-radius: var(--radius); padding: 30px;
  box-shadow: var(--shadow); transition: var(--transition);
  border-top: 4px solid var(--primary-light);
  position: relative; overflow: hidden;
}
.card:hover { transform: translateY(-6px) scale(1.01); box-shadow: var(--shadow-hover); }
.card .card-icon { font-size: 40px; margin-bottom: 16px; }
.card h3 { font-size: 20px; color: var(--primary); margin-bottom: 12px; }
.card p { color: var(--text-light); font-size: 15px; line-height: 1.8; }
.card.green { border-top-color: var(--accent); }
.card.orange { border-top-color: var(--warm); }
.card.blue { border-top-color: var(--primary-light); }

.cat-grid {
  display: grid;
  grid-template-columns: repeat(auto-fill, minmax(240px, 1fr));
  gap: 20px; margin-top: 40px;
}
.cat-card {
  background: var(--card); border-radius: var(--radius); padding: 30px 24px;
  text-align: center; cursor: pointer; transition: var(--transition);
  box-shadow: var(--shadow); text-decoration: none; color: var(--text);
}
.cat-card:hover { transform: translateY(-6px) scale(1.02); box-shadow: var(--shadow-hover); }
.cat-card .cat-icon { font-size: 48px; margin-bottom: 14px; }
.cat-card h3 { font-size: 18px; color: var(--primary); margin-bottom: 8px; }
.cat-card p { font-size: 13px; color: var(--text-light); }

.accordion { margin-bottom: 16px; }
.accordion-header {
  background: var(--card); padding: 20px 24px; border-radius: var(--radius);
  cursor: pointer; display: flex; justify-content: space-between; align-items: center;
  box-shadow: var(--shadow); transition: var(--transition);
  font-size: 17px; font-weight: 600; color: var(--primary);
}
.accordion-header:hover { background: #eef4fb; }
.accordion-header .arrow { transition: transform 0.3s ease; font-size: 20px; }
.accordion-header.open .arrow { transform: rotate(180deg); }
.accordion-body {
  max-height: 0; overflow: clip; transition: max-height 0.4s ease;
  background: var(--card); border-radius: 0 0 var(--radius) var(--radius); margin-top: -8px;
}
.accordion-body .inner { padding: 20px 24px 24px; color: var(--text-light); line-height: 2; }

.tabs { display: flex; gap: 8px; margin-bottom: 24px; flex-wrap: wrap; }
.tab-btn {
  padding: 12px 24px; background: var(--card);
  border: 2px solid #dde4eb; border-radius: 30px;
  cursor: pointer; font-size: 15px; font-family: inherit;
  color: var(--text-light); transition: var(--transition);
}
.tab-btn:hover { border-color: var(--primary-light); color: var(--primary); }
.tab-btn.active { background: var(--primary); color: #fff; border-color: var(--primary); }
.tab-content { display: none; animation: fadeIn 0.4s ease; }
.tab-content.active { display: block; }
@keyframes fadeIn { from { opacity: 0; transform: translateY(10px); } to { opacity: 1; transform: translateY(0); } }

.info-box {
  background: linear-gradient(135deg, #eaf4fb 0%, #e8f8f0 100%);
  border-radius: var(--radius); padding: 24px 28px; margin: 24px 0;
  border-left: 5px solid var(--primary-light);
}
.info-box.warning { background: linear-gradient(135deg, #fef9e7 0%, #fdebd0 100%); border-left-color: var(--warm); }
.info-box.success { background: linear-gradient(135deg, #e8f8f0 0%, #d5f5e3 100%); border-left-color: var(--accent); }
.info-box h4 { color: var(--primary); margin-bottom: 8px; font-size: 17px; }
.info-box p { color: var(--text-light); font-size: 15px; }

.link-btn {
  display: inline-flex; align-items: center; gap: 8px;
  padding: 12px 24px; background: var(--primary);
  color: #fff; text-decoration: none; border-radius: 30px;
  font-size: 15px; transition: var(--transition); margin: 6px;
}
.link-btn:hover { background: var(--primary-light); transform: translateY(-2px); }
.link-btn.green { background: var(--accent); }
.link-btn.green:hover { background: var(--accent-light); color: var(--text); }
.link-btn.orange { background: var(--warm-dark); }
.link-btn.orange:hover { background: var(--warm); color: var(--text); }

.styled-table {
  width: 100%; border-collapse: collapse; margin: 20px 0;
  background: var(--card); border-radius: var(--radius);
  overflow: hidden; box-shadow: var(--shadow);
}
.styled-table thead { background: var(--primary); color: #fff; }
.styled-table th { padding: 16px 20px; text-align: left; font-weight: 600; }
.styled-table td { padding: 14px 20px; border-bottom: 1px solid #eee; }
.styled-table tbody tr:hover { background: #f7fafc; }

.timeline { position: relative; padding-left: 40px; margin: 30px 0; }
.timeline::before {
  content: '';
  position: absolute; left: 12px; top: 0; bottom: 0;
  width: 3px;
  background: linear-gradient(to bottom, var(--primary-light), var(--accent));
  border-radius: 3px;
}
.timeline-item {
  position: relative; margin-bottom: 30px; padding: 24px;
  background: var(--card); border-radius: var(--radius); box-shadow: var(--shadow);
}
.timeline-item::before {
  content: ''; position: absolute;
  left: -34px; top: 30px;
  width: 16px; height: 16px;
  background: var(--accent); border-radius: 50%; border: 3px solid var(--bg);
}
.timeline-item h4 { color: var(--primary); font-size: 18px; margin-bottom: 8px; }
.timeline-item p { color: var(--text-light); }
.timeline-item .time-label {
  display: inline-block; background: var(--primary); color: #fff;
  padding: 4px 14px; border-radius: 20px; font-size: 13px; margin-bottom: 10px;
}

.stats-row {
  display: grid;
  grid-template-columns: repeat(auto-fill, minmax(200px, 1fr));
  gap: 20px; margin: 30px 0;
}
.stat-box {
  background: linear-gradient(135deg, var(--card) 0%, #f7fafc 100%);
  border-radius: var(--radius); padding: 24px; text-align: center;
  box-shadow: var(--shadow); border-bottom: 3px solid var(--primary-light);
  transition: var(--transition);
}
.stat-box:nth-child(2) { border-bottom-color: var(--accent); }
.stat-box:nth-child(3) { border-bottom-color: var(--warm); }
.stat-box:nth-child(4) { border-bottom-color: var(--warm-dark); }
.stat-box:hover { transform: translateY(-4px); box-shadow: var(--shadow-hover); }
.stat-box .stat-num {
  font-size: 36px; font-weight: 800;
  background: linear-gradient(135deg, var(--primary), var(--accent));
  -webkit-background-clip: text; -webkit-text-fill-color: transparent; background-clip: text;
}
.stat-box .stat-label { color: var(--text-light); font-size: 14px; margin-top: 6px; }

.carepedia-cta {
  background: linear-gradient(135deg, #1A73E8, #00C9A7);
  padding: 48px 24px; text-align: center; color: #fff;
}
.carepedia-cta h3 { font-size: 24px; font-weight: 700; margin-bottom: 12px; }
.carepedia-cta p { font-size: 16px; opacity: 0.9; margin-bottom: 24px; max-width: 500px; margin-left: auto; margin-right: auto; }
.carepedia-cta .cta-btn {
  display: inline-flex; align-items: center; gap: 8px;
  padding: 14px 32px; background: #fff; color: #1A73E8;
  text-decoration: none; border-radius: 30px; font-size: 16px; font-weight: 700;
  font-family: inherit; transition: all 0.3s ease; box-shadow: 0 4px 16px rgba(0,0,0,0.15);
}
.carepedia-cta .cta-btn:hover { transform: translateY(-2px); box-shadow: 0 8px 24px rgba(0,0,0,0.2); }

.credit-bar {
  display: flex; align-items: center; justify-content: center; gap: 16px; flex-wrap: wrap;
  padding: 14px 20px; font-size: 14px; color: rgba(255,255,255,0.85); position: relative; z-index: 1;
}
.credit-bar span { opacity: 0.9; }
.portal-request-btn {
  display: inline-flex; align-items: center; gap: 8px;
  padding: 10px 22px; background: var(--primary-light); color: #fff;
  text-decoration: none; border-radius: 30px; font-size: 14px;
  font-family: inherit; font-weight: 600; transition: var(--transition);
  box-shadow: 0 2px 12px rgba(0,0,0,0.15);
}
.portal-request-btn:hover { background: var(--primary); transform: translateY(-2px); box-shadow: 0 4px 20px rgba(0,0,0,0.2); }

.footer {
  background: var(--primary); color: rgba(255,255,255,0.8);
  text-align: center; padding: 40px; font-size: 14px;
}

.scroll-top {
  position: fixed; bottom: 30px; left: 30px;
  width: 50px; height: 50px; background: var(--primary);
  color: #fff; border: none; border-radius: 50%;
  font-size: 22px; cursor: pointer; box-shadow: var(--shadow);
  transition: var(--transition); opacity: 0; pointer-events: none; z-index: 999;
}
.scroll-top.visible { opacity: 1; pointer-events: auto; }
.scroll-top:hover { background: var(--primary-light); transform: translateY(-3px); }

.search-box { position: relative; margin: 0 auto; }
.search-box input {
  width: 100%; padding: 14px 20px 14px 50px;
  border: 2px solid rgba(15,76,117,0.15); border-radius: 30px;
  font-size: 16px; font-family: 'Rubik', sans-serif;
  background: var(--card); color: var(--text); transition: var(--transition);
  box-sizing: border-box;
}
.search-box input:focus { outline: none; border-color: var(--primary-light); box-shadow: 0 0 0 4px rgba(50,130,184,0.1); }
.search-box .search-icon {
  position: absolute; left: 18px; top: 50%;
  transform: translateY(-50%); font-size: 20px; pointer-events: none;
}

.sidebar-overlay {
  display: none; position: fixed; top: 0; left: 0; right: 0; bottom: 0;
  background: rgba(0,0,0,0.5); z-index: 999; opacity: 0; transition: opacity 0.3s ease;
}
.sidebar-overlay.active { display: block; opacity: 1; }

@media (max-width: 900px) {
  .sidebar { transform: translateX(-100%); width: 270px; }
  .sidebar.open { transform: translateX(0); }
  .menu-toggle { display: block; }
  .main { margin-left: 0; }
  .hero { padding: 60px 30px; }
  .section { padding: 40px 24px; }
}

@media (max-width: 768px) {
  .sidebar { transform: translateX(-100%); width: 260px; }
  .sidebar.open { transform: translateX(0); }
  .menu-toggle { display: block; }
  .main { margin-left: 0; }
  .hero { padding: 40px 20px 36px; }
  .hero h1 { font-size: 28px; line-height: 1.3; }
  .hero .greeting { font-size: 16px; line-height: 1.7; }
  .hero .subtitle { font-size: 14px; }
  .section { padding: 28px 16px; }
  .section-header { flex-direction: column; align-items: flex-start; gap: 8px; margin-bottom: 24px; padding-bottom: 14px; }
  .section-header .sec-icon { font-size: 32px; }
  .section-header h2 { font-size: 24px; }
  .section-header p { font-size: 14px; }
  .cards-grid { grid-template-columns: 1fr; gap: 16px; margin-bottom: 24px; }
  .card { padding: 20px; }
  .card:hover { transform: none; }
  .cat-card:hover { transform: none; }
  .stat-box:hover { transform: none; }
  .link-btn:hover { transform: none; }
  .portal-request-btn:hover { transform: none; }
  .scroll-top:hover { transform: none; }
  .sidebar nav a:hover { transform: none; }
  .card .card-icon { font-size: 32px; margin-bottom: 10px; }
  .card h3 { font-size: 17px; }
  .card p { font-size: 14px; }
  .cat-grid { grid-template-columns: repeat(2, 1fr); gap: 12px; margin-top: 24px; }
  .cat-card { padding: 18px 12px; }
  .cat-card .cat-icon { font-size: 32px; margin-bottom: 8px; }
  .cat-card h3 { font-size: 14px; }
  .cat-card p { font-size: 11px; }
  .stats-row { grid-template-columns: repeat(2, 1fr); gap: 12px; margin: 20px 0; }
  .stat-box { padding: 16px 10px; }
  .stat-box .stat-num { font-size: 26px; }
  .stat-box .stat-label { font-size: 12px; }
  .tabs { gap: 6px; margin-bottom: 16px; }
  .tab-btn { padding: 8px 14px; font-size: 13px; border-radius: 20px; }
  .styled-table { display: block; overflow-x: auto; -webkit-overflow-scrolling: touch; font-size: 13px; }
  .styled-table th { padding: 10px 12px; font-size: 13px; white-space: nowrap; }
  .styled-table td { padding: 10px 12px; font-size: 13px; min-width: 100px; }
  .info-box { padding: 16px 18px; margin: 16px 0; }
  .info-box h4 { font-size: 15px; }
  .info-box p { font-size: 13px; }
  .accordion-header { padding: 14px 16px; font-size: 15px; }
  .accordion-body .inner { padding: 14px 16px 18px; font-size: 14px; line-height: 1.9; }
  .timeline { padding-left: 30px; margin: 20px 0; }
  .timeline-item { padding: 16px; margin-bottom: 20px; }
  .timeline-item::before { left: -24px; width: 12px; height: 12px; top: 22px; }
  .timeline-item h4 { font-size: 16px; }
  .timeline-item p { font-size: 13px; }
  .link-btn { padding: 10px 16px; font-size: 13px; margin: 4px 2px; }
  .search-box input { padding: 12px 18px 12px 40px; font-size: 14px; }
  .footer { padding: 28px 16px; font-size: 13px; }
  .scroll-top { width: 42px; height: 42px; font-size: 18px; bottom: 20px; left: 16px; }
}

@media (max-width: 380px) {
  .hero h1 { font-size: 24px; }
  .hero .greeting { font-size: 15px; }
  .cat-grid { grid-template-columns: 1fr 1fr; gap: 8px; }
  .cat-card { padding: 14px 8px; }
  .cat-card .cat-icon { font-size: 26px; }
  .cat-card h3 { font-size: 13px; }
  .cat-card p { display: none; }
  .stats-row { grid-template-columns: 1fr 1fr; gap: 8px; }
  .stat-box .stat-num { font-size: 22px; }
  .section { padding: 20px 12px; }
  .tab-btn { padding: 7px 10px; font-size: 12px; }
}

.disclaimer-banner {
  background: linear-gradient(135deg, #FFF3E0, #FFF8E1);
  border-bottom: 2px solid #FFB74D;
  padding: 10px 20px; text-align: center; font-size: 13px; color: #5D4037;
  position: relative; z-index: 1500;
  display: flex; align-items: center; justify-content: center; gap: 8px; flex-wrap: wrap;
}
.disclaimer-banner strong { color: #E65100; }
.disclaimer-banner a { color: #1A73E8; text-decoration: underline; font-weight: 600; }
.disclaimer-banner a:hover { color: #0D47A1; }
@media (max-width: 768px) { .disclaimer-banner { font-size: 12px; padding: 8px 12px; } }
</style>
<script src="https://code.iconify.design/iconify-icon/2.1.0/iconify-icon.min.js" defer></script>
</head>
<body>

<!-- DISCLAIMER BANNER -->
<div class="disclaimer-banner">
  <span>&#9888;&#65039;</span>
  <span><strong>This is not medical advice.</strong> Always consult your doctor. <a href="/disclaimer">Full legal disclaimer &rarr;</a></span>
</div>

<!-- SCROLL PROGRESS BAR -->
<div class="scroll-progress"><div class="bar" id="progressBar"></div></div>

<!-- MOBILE OVERLAY -->
<div class="sidebar-overlay" id="sidebarOverlay" onclick="closeMenu()"></div>

<!-- MOBILE MENU TOGGLE -->
<button class="menu-toggle" id="menuToggle" onclick="toggleMenu()">&#9776;</button>

<!-- SIDEBAR -->
<aside class="sidebar" id="sidebar">
  <div class="logo">
    <div class="icon">&#128260;</div>
    <h2>Dystonia DYT1 Hub</h2>
  </div>
  <nav>
    <a href="#home" class="active" onclick="navigate(this)"><span class="nav-icon">&#127968;</span>Home</a>
    <a href="#about" onclick="navigate(this)"><span class="nav-icon">&#128214;</span>What is Dystonia DYT1?</a>
    <a href="#treatments" onclick="navigate(this)"><span class="nav-icon">&#128138;</span>Treatments</a>
    <a href="#trials" onclick="navigate(this)"><span class="nav-icon">&#128300;</span>Clinical Trials</a>
    <a href="#research" onclick="navigate(this)"><span class="nav-icon">&#129516;</span>New Research</a>
    <a href="#researchers" onclick="navigate(this)"><span class="nav-icon">&#128104;&#8205;&#128300;</span>Leading Researchers</a>
    <a href="#global" onclick="navigate(this)"><span class="nav-icon">&#127758;</span>Global Patient Community</a>
    <a href="#lifestyle" onclick="navigate(this)"><span class="nav-icon">&#127939;</span>Lifestyle &amp; Rehabilitation</a>
    <a href="#psychology" onclick="navigate(this)"><span class="nav-icon">&#129504;</span>Psychological Approach</a>
    <a href="#stories" onclick="navigate(this)"><span class="nav-icon">&#11088;</span>Success Stories</a>
    <a href="#resources" onclick="navigate(this)"><span class="nav-icon">&#128279;</span>Links &amp; Resources</a>
  </nav>
</aside>

<!-- MAIN CONTENT -->
<div class="main">

  <!-- HERO -->
  <section class="hero" id="home">
    <div class="credit-bar">
      <span>Built by <strong>Yuval Keshtcher</strong> and his robot assistants</span>
      <a href="https://carepedia.org/#contact" target="_blank" class="portal-request-btn">
        &#43; Want a portal for another condition?
      </a>
    </div>
    <div class="hero-content">
      <h1>Dystonia DYT1 Learning Center</h1>
      <p class="greeting">
        One place with in-depth information, current research, and practical tools<br>
        for people living with Dystonia DYT1 and their families.
      </p>
      <p class="subtitle">
        DYT1 dystonia is a rare genetic movement disorder with especially high prevalence among Ashkenazi Jewish populations worldwide. Here you will find current research, leading researchers, clinical trials, and patient advocacy resources.
      </p>
      <div class="search-box" style="margin-top: 30px; max-width: 600px;">
        <span class="search-icon">&#128269;</span>
        <input type="text" id="portalSearch" placeholder="Search the portal..." oninput="searchPortal(this.value)">
        <button class="search-clear" id="searchClear" onclick="clearSearch()" style="display:none;">&#10005;</button>
      </div>
      <div id="searchResults" style="display:none; margin-top: 16px; max-width: 600px;"></div>
    </div>
  </section>

  <!-- QUICK NAVIGATION -->
  <section class="section fade-in" style="padding-bottom: 20px;">
    <div class="cat-grid">
      <a class="cat-card" href="#about" onclick="navigateTo('about')">
        <div class="cat-icon">&#128214;</div>
        <h3>What is Dystonia DYT1?</h3>
        <p>Genetics, symptoms, and diagnosis</p>
      </a>
      <a class="cat-card" href="#treatments" onclick="navigateTo('treatments')">
        <div class="cat-icon">&#128138;</div>
        <h3>Treatments</h3>
        <p>Medications, botulinum toxin, deep brain stimulation</p>
      </a>
      <a class="cat-card" href="#trials" onclick="navigateTo('trials')">
        <div class="cat-icon">&#128300;</div>
        <h3>Clinical Trials</h3>
        <p>Active research worldwide</p>
      </a>
      <a class="cat-card" href="#research" onclick="navigateTo('research')">
        <div class="cat-icon">&#129516;</div>
        <h3>New Research</h3>
        <p>CRISPR, gene therapy, and breakthroughs</p>
      </a>
      <a class="cat-card" href="#researchers" onclick="navigateTo('researchers')">
        <div class="cat-icon">&#128104;&#8205;&#128300;</div>
        <h3>Leading Researchers</h3>
        <p>Who is driving global research</p>
      </a>
      <a class="cat-card" href="#global" onclick="navigateTo('global')">
        <div class="cat-icon">&#127758;</div>
        <h3>Global Patient Community</h3>
        <p>International patient organizations and advocacy</p>
      </a>
      <a class="cat-card" href="#lifestyle" onclick="navigateTo('lifestyle')">
        <div class="cat-icon">&#127939;</div>
        <h3>Lifestyle &amp; Rehabilitation</h3>
        <p>Physiotherapy, exercise, and quality of life</p>
      </a>
      <a class="cat-card" href="#resources" onclick="navigateTo('resources')">
        <div class="cat-icon">&#128279;</div>
        <h3>Links &amp; Resources</h3>
        <p>Organizations, databases, and further reading</p>
      </a>
    </div>
  </section>

  <!-- SECTION: ABOUT -->
  <section class="section fade-in" id="about">
    <div class="section-header">
      <span class="sec-icon">&#128214;</span>
      <div>
        <h2>What is Dystonia DYT1?</h2>
        <p>A rare genetic movement disorder with elevated prevalence in the Ashkenazi Jewish population</p>
      </div>
    </div>

    <div class="stats-row">
      <div class="stat-box"><div class="stat-num">1:3,000</div><div class="stat-label">Carrier frequency in Ashkenazi Jews</div></div>
      <div class="stat-box"><div class="stat-num">30%</div><div class="stat-label">Penetrance — only 30% of carriers develop symptoms</div></div>
      <div class="stat-box"><div class="stat-num">~9</div><div class="stat-label">Average age of symptom onset (years)</div></div>
      <div class="stat-box"><div class="stat-num">350 yrs</div><div class="stat-label">Age of the Ashkenazi founder mutation</div></div>
    </div>

    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">&#129516;</div>
        <h3>The Genetics</h3>
        <p>DYT1 dystonia is caused by a mutation in the TOR1A gene on chromosome 9q34. The most common mutation is a 3-base-pair deletion (GAG) in exon 5, which causes loss of a glutamic acid residue in the TorsinA protein. Inheritance is autosomal dominant with only ~30% penetrance, meaning not every carrier will develop symptoms.</p>
      </div>
      <div class="card green">
        <div class="card-icon">&#128118;</div>
        <h3>The Symptoms</h3>
        <p>Symptoms typically begin in childhood, around age 9, and usually start in an arm or leg. They may progress to involuntary muscle contractions causing twisting movements and abnormal postures. In 60–70% of cases the dystonia spreads to involve multiple body regions (generalized dystonia).</p>
      </div>
      <div class="card orange">
        <div class="card-icon">&#128300;</div>
        <h3>The Diagnosis</h3>
        <p>Diagnosis is based on a combination of clinical examination and genetic testing to identify the GAG deletion in TOR1A. Genetic testing alone is not sufficient because only 30% of mutation carriers develop symptoms. The diagnosis also requires ruling out other causes of dystonia.</p>
      </div>
    </div>

    <div class="info-box">
      <h4>The Ashkenazi Founder Mutation</h4>
      <p>More than 90% of early-onset dystonia cases among Ashkenazi Jews arise from a single founder mutation that appeared approximately 350 years ago, originating in the northern Pale of Settlement (Lithuania and Belarus). Carrier frequency in the Ashkenazi Jewish population is 3–5 times higher than in the general population worldwide.</p>
    </div>

    <h3 style="color: var(--primary); margin: 30px 0 16px;">Frequently Asked Questions</h3>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <span>What is the difference between DYT1 dystonia and other types of dystonia?</span>
        <span class="arrow">&#9660;</span>
      </div>
      <div class="accordion-body">
        <div class="inner">DYT1 is a primary genetic dystonia — it is caused by a specific mutation in the TOR1A gene, not by brain injury or another external cause. It begins at a young age (typically before age 26), in contrast to focal dystonias that appear in adulthood. It also tends to spread and become more generalized over time.</div>
      </div>
    </div>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <span>Will everyone who carries the mutation develop dystonia?</span>
        <span class="arrow">&#9660;</span>
      </div>
      <div class="accordion-body">
        <div class="inner">No. The penetrance of the DYT1 mutation is only about 30%. This means that out of 10 people carrying the mutation, only about 3 will develop symptoms on average. The reasons for incomplete penetrance are still being studied, but additional environmental and genetic factors likely play a role.</div>
      </div>
    </div>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <span>Is genetic testing available?</span>
        <span class="arrow">&#9660;</span>
      </div>
      <div class="accordion-body">
        <div class="inner">Yes. DNA testing to identify the GAG deletion in TOR1A is available and recommended for families with a history of early-onset dystonia. The test is particularly relevant for families of Ashkenazi Jewish descent. It is important to consult with a genetic counselor before and after testing to fully understand the implications.</div>
      </div>
    </div>
    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <span>Does DYT1 dystonia progress with age?</span>
        <span class="arrow">&#9660;</span>
      </div>
      <div class="accordion-body">
        <div class="inner">Symptoms generally progress during the first few years after onset but tend to plateau over time. In most patients symptoms reach a peak and then remain stable. In rare cases there can be an acute worsening (dystonic storm) that requires emergency treatment.</div>
      </div>
    </div>
  </section>

  <!-- SECTION: TREATMENTS -->
  <section class="section fade-in" id="treatments">
    <div class="section-header">
      <span class="sec-icon">&#128138;</span>
      <div>
        <h2>Treatments</h2>
        <p>Three main therapeutic approaches: medications, botulinum toxin, and surgery</p>
      </div>
    </div>

    <div class="tabs" data-tab-group="treatments">
      <button class="tab-btn active" data-tab="meds" onclick="switchTab('treatments','meds')">Medications</button>
      <button class="tab-btn" data-tab="botox" onclick="switchTab('treatments','botox')">Botulinum Toxin</button>
      <button class="tab-btn" data-tab="dbs" onclick="switchTab('treatments','dbs')">Deep Brain Stimulation (DBS)</button>
      <button class="tab-btn" data-tab="questions" onclick="switchTab('treatments','questions')">Questions for Your Doctor</button>
    </div>

    <div class="tab-content active" data-tab-content="treatments" data-tab="meds">
      <h3 style="color: var(--primary); margin-bottom: 16px;">Medications for DYT1 Dystonia</h3>
      <p style="margin-bottom: 20px;">Four main drug classes are used to treat generalized dystonia:</p>
      <table class="styled-table">
        <thead><tr><th>Medication</th><th>Class</th><th>Mechanism</th><th>Notes</th></tr></thead>
        <tbody>
          <tr><td>Trihexyphenidyl (Artane)</td><td>Anticholinergic</td><td>Blocks acetylcholine in the brain</td><td>First-line for generalized dystonia. Doses up to 45 mg/day</td></tr>
          <tr><td>Baclofen</td><td>Muscle relaxant</td><td>GABA-B agonist</td><td>Effective in combination with trihexyphenidyl. ~30 mg/day</td></tr>
          <tr><td>Clonazepam</td><td>Benzodiazepine</td><td>Enhances GABA activity</td><td>Helps reduce spasms and muscle tension</td></tr>
          <tr><td>Levodopa</td><td>Dopaminergic</td><td>Raises dopamine levels</td><td>Tried first to rule out dopa-responsive dystonia</td></tr>
        </tbody>
      </table>

      <div class="info-box">
        <h4>Pharmacological Treatment Approach</h4>
        <p>Treatment is individualized for each patient. Typically medications are trialed sequentially: first levodopa (to rule out DRD), then trihexyphenidyl, baclofen, and sometimes combinations. Doses are increased gradually to minimize side effects.</p>
      </div>
    </div>

    <div class="tab-content" data-tab-content="treatments" data-tab="botox">
      <h3 style="color: var(--primary); margin-bottom: 16px;">Botulinum Toxin Injections</h3>
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon">&#128137;</div>
          <h3>When Is It Appropriate?</h3>
          <p>Botulinum toxin is the first-line treatment for focal or segmental dystonia, with success rates of approximately 73%. DYT1 patients with focal or segmental symptoms also benefit significantly from injections. Injections are administered every 3–6 months.</p>
        </div>
        <div class="card green">
          <div class="card-icon">&#127919;</div>
          <h3>How Does It Work?</h3>
          <p>The toxin is injected directly into the affected muscles and blocks the release of acetylcholine at the neuromuscular junction, causing relaxation of the muscle. Effects begin within days and last for months.</p>
        </div>
        <div class="card orange">
          <div class="card-icon">&#9878;&#65039;</div>
          <h3>Benefits and Limitations</h3>
          <p>Highly effective for focal symptoms. Less effective for generalized dystonia. Side effects can include temporary muscle weakness and difficulty swallowing (with neck injections). There is no significant systemic risk.</p>
        </div>
      </div>
    </div>

    <div class="tab-content" data-tab-content="treatments" data-tab="dbs">
      <h3 style="color: var(--primary); margin-bottom: 16px;">Deep Brain Stimulation (DBS)</h3>
      <div class="info-box success">
        <h4>DBS Is the Most Effective Treatment for Generalized DYT1 Dystonia</h4>
        <p>Studies show 50–90% improvement on the Burke-Fahn-Marsden (BFM) scale in DYT1 patients who undergo DBS surgery. Results are especially good when surgery is performed early, in younger patients.</p>
      </div>
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon">&#9889;</div>
          <h3>How Does It Work?</h3>
          <p>Electrodes are implanted in the globus pallidus interna (GPi) and connected to a pulse generator implanted in the chest. The device delivers electrical impulses that modulate the abnormal brain activity driving dystonia.</p>
        </div>
        <div class="card green">
          <div class="card-icon">&#128200;</div>
          <h3>Long-Term Outcomes</h3>
          <p>Follow-up studies of up to 10 years (Isaias et al., 2009) show that improvement is sustained over time. A 2025 study confirmed that DBS significantly improves motor function and daily functioning, with a clear advantage over secondary dystonia.</p>
        </div>
        <div class="card orange">
          <div class="card-icon">&#9200;</div>
          <h3>When to Consider Surgery?</h3>
          <p>Early referral for children and young adults with medication-refractory DYT1 dystonia can substantially improve outcomes. Shorter disease duration predicts greater long-term improvement.</p>
        </div>
      </div>
    </div>

    <div class="tab-content" data-tab-content="treatments" data-tab="questions">
      <h3 style="color: var(--primary); margin-bottom: 16px;">Important Questions to Ask Your Doctor</h3>
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon">&#10067;</div>
          <h3>About Diagnosis and Genetics</h3>
          <p>
            1. Does my family need genetic testing?<br>
            2. What does a positive carrier result mean?<br>
            3. Is genetic counseling available?<br>
            4. What is the chance my children will inherit the mutation?
          </p>
        </div>
        <div class="card green">
          <div class="card-icon">&#128138;</div>
          <h3>About Medications</h3>
          <p>
            1. Which medication is right for my situation?<br>
            2. What side effects should I expect?<br>
            3. How long until I see improvement?<br>
            4. Can multiple medications be combined?
          </p>
        </div>
        <div class="card orange">
          <div class="card-icon">&#9889;</div>
          <h3>About DBS</h3>
          <p>
            1. Am I a candidate for DBS surgery?<br>
            2. What are the risks of the procedure?<br>
            3. What are the success rates for my situation?<br>
            4. What follow-up is required after surgery?
          </p>
        </div>
      </div>
    </div>
  </section>

  <!-- SECTION: CLINICAL TRIALS -->
  <section class="section fade-in" id="trials">
    <div class="section-header">
      <span class="sec-icon">&#128300;</span>
      <div>
        <h2>Clinical Trials</h2>
        <p>Active research in DYT1 dystonia and related movement disorders</p>
      </div>
    </div>

    <div class="info-box warning">
      <h4>Important to Know</h4>
      <p>As of 2026, there are no approved gene therapy clinical trials for hereditary dystonia. Most active studies focus on understanding the natural history of the disease, identifying biomarkers, and building the infrastructure for future interventional trials.</p>
    </div>

    <div class="timeline">
      <div class="timeline-item">
        <span class="time-label">Active | NCT01373424</span>
        <h4>Dystonia Coalition: Natural History and Biological Sample Repository</h4>
        <p>A multicenter study (58 centers across North America, Europe, Asia, and Australia) collecting clinical data and samples from 5,000+ dystonia patients including DYT1. Goals: develop and validate rating scales, identify biomarkers, and create infrastructure for further research.</p>
        <a href="https://clinicaltrials.gov/study/NCT01373424" target="_blank" class="link-btn" style="margin-top:12px;">ClinicalTrials.gov</a>
      </div>
      <div class="timeline-item">
        <span class="time-label">Active | Duke University</span>
        <h4>Dystonia Biomarker Discovery</h4>
        <p>A study aiming to identify biomarkers for dystonia in order to improve diagnosis, predict disease severity, and guide treatment. The study is specifically recruiting DYT1 patients and their family members.</p>
      </div>
      <div class="timeline-item">
        <span class="time-label">Active | NINDS</span>
        <h4>TMS (Transcranial Magnetic Stimulation) Study in Dystonia</h4>
        <p>The National Institute of Neurological Disorders and Stroke (NINDS) is investigating intracortical inhibition in generalized dystonia of known genetic origin (DYT1) using TMS. The goal is to understand the brain's pathophysiology in DYT1.</p>
      </div>
      <div class="timeline-item">
        <span class="time-label">Active | DMRF</span>
        <h4>Drug Repurposing Screen for DYT1 Dystonia</h4>
        <p>The Dystonia Medical Research Foundation (DMRF) is funding an in vivo drug screen to identify existing approved medications that could treat DYT1 dystonia. This approach can significantly accelerate the path to new treatments.</p>
      </div>
    </div>

    <div style="text-align:center; margin-top: 30px;">
      <a href="https://clinicaltrials.gov/search?cond=DYT1+dystonia" target="_blank" class="link-btn">Search Trials on ClinicalTrials.gov</a>
      <a href="https://dc.rarediseasesnetwork.org/" target="_blank" class="link-btn green">Dystonia Coalition</a>
    </div>
  </section>

  <!-- SECTION: RESEARCH -->
  <section class="section fade-in" id="research">
    <div class="section-header">
      <span class="sec-icon">&#129516;</span>
      <div>
        <h2>New Research</h2>
        <p>Breakthroughs in basic and clinical research on DYT1 dystonia</p>
      </div>
    </div>

    <div class="tabs" data-tab-group="research">
      <button class="tab-btn active" data-tab="gene" onclick="switchTab('research','gene')">Gene Therapy &amp; CRISPR</button>
      <button class="tab-btn" data-tab="mechanism" onclick="switchTab('research','mechanism')">Understanding the Mechanism</button>
      <button class="tab-btn" data-tab="targets" onclick="switchTab('research','targets')">Novel Therapeutic Targets</button>
    </div>

    <div class="tab-content active" data-tab-content="research" data-tab="gene">
      <h3 style="color: var(--primary); margin-bottom: 16px;">CRISPR and Gene Therapy</h3>
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon">&#9986;&#65039;</div>
          <h3>Allele-Specific CRISPR/Cas9</h3>
          <p>Research (Bhatt et al., 2020) demonstrated that CRISPR-Cas9 can selectively inactivate the mutant copy of the TOR1A gene while preserving the normal copy. Treated cells showed full phenotypic and functional recovery.</p>
        </div>
        <div class="card green">
          <div class="card-icon">&#129514;</div>
          <h3>Compact NmCas9 System (2024)</h3>
          <p>A 2024 study (bioRxiv) described the use of a compact CRISPR/NmCas9 system that targets the DELTA-GAG mutation with high precision. The compact design is better suited for packaging into AAV vectors, bringing in vivo delivery closer to clinical reality.</p>
        </div>
        <div class="card orange">
          <div class="card-icon">&#128300;</div>
          <h3>SaCas9-KKH in Neural Stem Cells (2025)</h3>
          <p>A 2025 study optimized an AAV vector with SaCas9-KKH in human neural progenitor cells (hNPCs) from DYT1 patients. Non-invasive detection of gene editing was demonstrated in xenograft mice, opening new avenues for monitoring gene therapy outcomes.</p>
        </div>
      </div>

      <div class="info-box">
        <h4>RNA Interference (RNAi)</h4>
        <p>Another approach uses siRNA (small interfering RNA) to specifically silence the mutant copy of TOR1A mRNA. In treated cells, the mutant-specific siRNA reduced mutant TorsinA levels to less than 1% of controls, with minimal effect on the normal copy — a highly promising therapeutic strategy.</p>
      </div>
    </div>

    <div class="tab-content" data-tab-content="research" data-tab="mechanism">
      <h3 style="color: var(--primary); margin-bottom: 16px;">Understanding Disease Mechanisms</h3>
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon">&#129504;</div>
          <h3>The Role of the Cerebellum</h3>
          <p>New research shows the cerebellum plays a key role in DYT1 dystonia. Silencing TorsinA specifically in the cerebellum (but not the basal ganglia) was sufficient to cause dystonia in mice. A 2026 study (Frontiers in Dystonia) validated a new cerebellar knockdown model using Cre-loxP recombination.</p>
        </div>
        <div class="card green">
          <div class="card-icon">&#128260;</div>
          <h3>Nuclear Pore Complexes (NPCs)</h3>
          <p>Research in Nature Cell Biology (2024, UT Southwestern) discovered that TorsinA determines where nuclear pore complexes are positioned during a critical period of neuronal development. This is a key finding for understanding why DYT1 symptoms begin in childhood.</p>
        </div>
        <div class="card orange">
          <div class="card-icon">&#128270;</div>
          <h3>LMNB1 and Nuclear Transport</h3>
          <p>iPSC-derived neurons from DYT1 patients revealed disruption of LMNB1 (Lamin B1) and impaired nucleus-to-cytoplasm transport. Overexpression of RANBP17 restored transport and improved neurodevelopmental defects (Journal of Neuroscience, 2024).</p>
        </div>
      </div>
    </div>

    <div class="tab-content" data-tab-content="research" data-tab="targets">
      <h3 style="color: var(--primary); margin-bottom: 16px;">Novel Therapeutic Targets</h3>
      <div class="cards-grid">
        <div class="card">
          <div class="card-icon">&#127919;</div>
          <h3>TorsinB as a Compensatory Protein</h3>
          <p>Research in eLife showed that TorsinB can compensate for the lack of functional TorsinA. Overexpression of TorsinB rescued abnormal movements and neurodegeneration in DYT1 mouse models. Reducing TorsinB caused worsening. This opens a new therapeutic direction: upregulating TorsinB levels.</p>
        </div>
        <div class="card green">
          <div class="card-icon">&#129516;</div>
          <h3>CLCC1 as a Novel Binding Partner (2025)</h3>
          <p>A November 2025 study (bioRxiv) identified CLCC1 as a new binding partner of Torsin. Overexpression of CLCC1 was sufficient to rescue nuclear pore biogenesis defects and developmental abnormalities associated with Torsin deficiency — a promising new therapeutic target.</p>
        </div>
        <div class="card orange">
          <div class="card-icon">&#128138;</div>
          <h3>Drug Repurposing</h3>
          <p>The Dystonia Medical Research Foundation (DMRF) is funding a screen of existing approved drugs that may be effective against DYT1. Drug repurposing can significantly shorten the time from discovery to a new treatment for patients.</p>
        </div>
      </div>

      <div class="info-box warning">
        <h4>Critical Therapeutic Window</h4>
        <p>Research in JCI (Bhatt et al., 2021) showed that TorsinA restoration has a critical therapeutic window. In mice, TorsinA restoration was effective only when performed early. The implication: future genetic treatments for DYT1 will likely be most effective when given early in life — making early diagnosis all the more important.</p>
      </div>
    </div>
  </section>

  <!-- SECTION: RESEARCHERS -->
  <section class="section fade-in" id="researchers">
    <div class="section-header">
      <span class="sec-icon">&#128104;&#8205;&#128300;</span>
      <div>
        <h2>Leading Researchers Worldwide</h2>
        <p>Who is driving DYT1 dystonia research and where</p>
      </div>
    </div>

    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">&#127482;&#127480;</div>
        <h3>Prof. Susan Bressman</h3>
        <p><strong>Mount Sinai, New York</strong><br>A leading researcher in the genetics and epidemiology of DYT1. Contributed to identifying the Ashkenazi founder mutation and the clinical characterization of the disease. Principal investigator in natural history studies.</p>
      </div>
      <div class="card green">
        <div class="card-icon">&#127482;&#127480;</div>
        <h3>Prof. Laurie Ozelius</h3>
        <p><strong>Massachusetts General Hospital</strong><br>Leading geneticist who contributed to the discovery of the TOR1A gene in 1997. Researches the genome of various dystonias and identifies novel mutations. Partner in Dystonia Coalition research.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">&#127482;&#127480;</div>
        <h3>Dr. Nutan Sharma</h3>
        <p><strong>Massachusetts General Hospital, Harvard</strong><br>Investigates the cellular mechanisms of DYT1, including iPSC-derived neuron models. Published research on LMNB1 and nuclear transport. GeneReviews author for DYT-TOR1A.</p>
      </div>
      <div class="card blue">
        <div class="card-icon">&#127463;&#127466;</div>
        <h3>Prof. Rose Goodchild</h3>
        <p><strong>KU Leuven, Belgium</strong><br>Leading researcher in TorsinA biology. Discovered that TorsinB can compensate for TorsinA deficiency (eLife study). Investigates NPC mechanisms and novel therapeutic targets.</p>
      </div>
      <div class="card">
        <div class="card-icon">&#127482;&#127480;</div>
        <h3>Prof. Mark LeDoux</h3>
        <p><strong>University of Memphis</strong><br>Investigates the role of the cerebellum in dystonia. Published foundational research on knockout models and the link between TorsinA and cerebellar function. Leads research on shared molecular pathways in various dystonias.</p>
      </div>
      <div class="card green">
        <div class="card-icon">&#127465;&#127466;</div>
        <h3>Prof. Christoph Kamm</h3>
        <p><strong>University of Rostock, Germany</strong><br>Expert in the epidemiology of DYT1 in Europe and the genetic factors influencing penetrance. Researches the distribution of the GAG mutation outside the Ashkenazi population.</p>
      </div>
    </div>

    <div class="info-box">
      <h4>The Central Research Body: Dystonia Coalition</h4>
      <p>The Dystonia Coalition connects 58 clinical centers across North America, Europe, Asia, and Australia. Since its founding in 2009, it has led multicenter research on natural history, biomarkers, and phenotype of hereditary dystonias including DYT1. It is the world's largest dystonia research infrastructure.</p>
    </div>
  </section>

  <!-- SECTION: GLOBAL PATIENT COMMUNITY -->
  <section class="section fade-in" id="global">
    <div class="section-header">
      <span class="sec-icon">&#127758;</span>
      <div>
        <h2>Global Patient Community</h2>
        <p>International patient organizations, advocacy, and support networks worldwide</p>
      </div>
    </div>

    <div class="info-box success">
      <h4>Why Patient Advocacy Matters</h4>
      <p>Rare disease communities that are well-organized have historically been among the most effective forces in accelerating research funding, securing regulatory attention, and improving access to care. International organizations like DMRF, Dystonia Europe, and Tyler's Hope have fundamentally shaped the modern dystonia research landscape.</p>
    </div>

    <h3 style="color: var(--primary); margin: 30px 0 16px;">Major International Patient Organizations</h3>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">&#127482;&#127480;</div>
        <h3>Dystonia Medical Research Foundation (DMRF)</h3>
        <p>The leading international dystonia organization, headquartered in Chicago. Funds research, runs patient support groups, organizes symposia, and provides comprehensive educational resources. The DMRF has funded millions of dollars in dystonia research since 1976.</p>
        <a href="https://dystonia-foundation.org/" target="_blank" class="link-btn" style="margin-top:10px;">Visit DMRF</a>
      </div>
      <div class="card green">
        <div class="card-icon">&#127466;&#127482;</div>
        <h3>Dystonia Europe</h3>
        <p>The European umbrella organization working to raise awareness, fund research, and support dystonia patients and families across Europe. Connects national patient associations and advocates at the EU level for rare neurological diseases.</p>
        <a href="https://www.dystonia-europe.org/" target="_blank" class="link-btn green" style="margin-top:10px;">Visit Dystonia Europe</a>
      </div>
      <div class="card orange">
        <div class="card-icon">&#127468;&#127463;</div>
        <h3>Dystonia Society (UK)</h3>
        <p>The UK's leading dystonia charity, providing helpline support, local groups, professional training, and funding for research. Runs the UK's most comprehensive dystonia patient registry and publishes patient-friendly information materials.</p>
        <a href="https://www.dystonia.org.uk/" target="_blank" class="link-btn orange" style="margin-top:10px;">Visit Dystonia Society</a>
      </div>
    </div>

    <h3 style="color: var(--primary); margin: 40px 0 16px;">DYT1-Focused Organizations</h3>
    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">&#127775;</div>
        <h3>Tyler's Hope for a Dystonia Cure</h3>
        <p>Founded by the family of Tyler Seddon, who was diagnosed with DYT1 at age 7. Tyler's Hope concentrates specifically on DYT1 research, connecting leading scientists and funding targeted gene therapy and mechanistic research. Chapters across multiple countries.</p>
        <a href="https://www.tylershope.org/" target="_blank" class="link-btn" style="margin-top:10px;">Tyler's Hope</a>
      </div>
      <div class="card green">
        <div class="card-icon">&#128104;&#8205;&#128300;</div>
        <h3>Dystonia Coalition</h3>
        <p>A network of 58 research centers across 4 continents coordinating the world's largest natural history studies for dystonia. The Coalition has enrolled thousands of patients in longitudinal studies and is the primary engine for biomarker discovery in DYT1.</p>
        <a href="https://dc.rarediseasesnetwork.org/" target="_blank" class="link-btn green" style="margin-top:10px;">Dystonia Coalition</a>
      </div>
      <div class="card orange">
        <div class="card-icon">&#128101;</div>
        <h3>Rare Disease International (RDI)</h3>
        <p>A global federation of rare disease organizations that advocates at the United Nations and WHO for the rights and needs of all rare disease patients, including those with rare movement disorders like DYT1. Provides a policy framework for national advocacy.</p>
        <a href="https://www.rarediseasesinternational.org/" target="_blank" class="link-btn orange" style="margin-top:10px;">RDI</a>
      </div>
    </div>

    <h3 style="color: var(--primary); margin: 40px 0 16px;">How to Connect and Get Involved</h3>
    <div class="timeline">
      <div class="timeline-item">
        <span class="time-label">Step 1</span>
        <h4>Join a Patient Registry</h4>
        <p>Enroll in the DMRF patient registry or the Dystonia Coalition research database. Registries help researchers understand disease patterns and connect patients with relevant clinical trials. Enrollment is free and confidential.</p>
      </div>
      <div class="timeline-item">
        <span class="time-label">Step 2</span>
        <h4>Connect with Support Groups</h4>
        <p>DMRF and the Dystonia Society run in-person and virtual support groups in multiple countries. Sharing experiences with others who truly understand the condition significantly reduces the psychological burden of living with a rare disease.</p>
      </div>
      <div class="timeline-item">
        <span class="time-label">Step 3</span>
        <h4>Engage in Advocacy</h4>
        <p>Patient advocacy directly influences research funding, drug approval timelines, and healthcare policy. Contact your national rare disease alliance, participate in awareness campaigns, and share your story with legislators and policymakers.</p>
      </div>
      <div class="timeline-item">
        <span class="time-label">Step 4</span>
        <h4>Participate in Research</h4>
        <p>Volunteer for natural history studies, biomarker discovery projects, and — when available — interventional trials. Patient participation is the single most important factor enabling scientific progress in rare diseases.</p>
      </div>
    </div>
  </section>

  <!-- SECTION: LIFESTYLE -->
  <section class="section fade-in" id="lifestyle">
    <div class="section-header">
      <span class="sec-icon">&#127939;</span>
      <div>
        <h2>Lifestyle &amp; Rehabilitation</h2>
        <p>Physical therapy, exercise, and tools for improving quality of life</p>
      </div>
    </div>

    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">&#129336;</div>
        <h3>Physiotherapy</h3>
        <p>Targeted physiotherapy is an essential part of management. Stretching exercises to improve range of motion, strengthening of antagonist muscles, and balance and coordination training are all beneficial. Techniques such as Kinesiotaping and vibratory tactile stimulation can help modify movement patterns.</p>
      </div>
      <div class="card green">
        <div class="card-icon">&#129504;</div>
        <h3>Physical Exercise</h3>
        <p>Regular physical activity is strongly encouraged. Yoga, Pilates, and swimming are particularly suitable. Aquatic exercise reduces the load on affected muscles. Seated exercise is also appropriate when balance is impaired. Exercise benefits both physical function and mental health.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">&#129504;</div>
        <h3>Mental Health</h3>
        <p>Living with chronic dystonia affects mental wellbeing. Psychological therapy (CBT), support groups, and mindfulness practices are all helpful. Biofeedback has demonstrated effectiveness for strengthening motor control and improving body awareness in dystonia patients.</p>
      </div>
    </div>

    <div class="info-box">
      <h4>Holistic Approach to Rehabilitation</h4>
      <p>A 2025 study (Frontiers in Dystonia) emphasizes that a holistic approach to neurological rehabilitation in dystonia significantly reduces disability and improves quality of life. The combination of physiotherapy, occupational therapy, psychological support, and adapted physical exercise produces the best outcomes.</p>
    </div>

    <div class="cards-grid" style="margin-top: 30px;">
      <div class="card">
        <div class="card-icon">&#128295;</div>
        <h3>Occupational Therapy</h3>
        <p>Occupational therapists help patients adapt daily activities, work environments, and home settings to reduce the functional impact of dystonia. Adaptive equipment, ergonomic modifications, and compensatory strategies can maintain independence in tasks such as writing, dressing, and cooking.</p>
      </div>
      <div class="card green">
        <div class="card-icon">&#127909;</div>
        <h3>Music and Arts Therapies</h3>
        <p>Some DYT1 patients experience temporary relief of symptoms during specific motor tasks — a phenomenon known as "sensory tricks" or geste antagoniste. Music therapy and certain rhythmic motor training approaches have been reported to help modulate dystonic movements in case series.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">&#128137;</div>
        <h3>Pain Management</h3>
        <p>Chronic pain affects a significant proportion of people with generalized dystonia. A multidisciplinary pain management approach combining physical modalities, psychological techniques, and appropriate pharmacotherapy is recommended. A pain specialist referral should be considered when pain is inadequately controlled.</p>
      </div>
    </div>
  </section>

  <!-- SECTION: PSYCHOLOGY -->
  <section class="section fade-in" id="psychology">
    <div class="section-header">
      <span class="sec-icon">&#129504;</span>
      <div>
        <h2>Psychological Approach</h2>
        <p>Depression, anxiety, social stigma, and evidence-based coping strategies</p>
      </div>
    </div>

    <div class="stats-row">
      <div class="stat-box"><div class="stat-num">70%</div><div class="stat-label">of dystonia patients experience depression or anxiety during their lifetime</div></div>
      <div class="stat-box"><div class="stat-num">x10</div><div class="stat-label">social anxiety is 10 times more prevalent than in the general population</div></div>
      <div class="stat-box"><div class="stat-num">#1</div><div class="stat-label">Depression and anxiety are the strongest predictors of quality of life impairment</div></div>
      <div class="stat-box"><div class="stat-num">57%</div><div class="stat-label">of cervical dystonia patients have concurrent anxiety and depression</div></div>
    </div>

    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">&#128530;</div>
        <h3>Depression and Anxiety in Dystonia</h3>
        <p>Research shows that 40–70% of dystonia patients experience depression or anxiety during their lifetime. A striking finding: psychiatric disturbances in dystonia often appear <strong>before</strong> the onset of motor symptoms. This suggests a shared neurobiological mechanism (basal ganglia circuits and the limbic system) rather than merely a psychological reaction to disability. A 2004 study (Heiman et al., Neurology) found that DYT1 mutation carriers <strong>without motor symptoms</strong> are at elevated risk for recurrent depression, strengthening the genetic link.</p>
      </div>
      <div class="card green">
        <div class="card-icon">&#128101;</div>
        <h3>Body Image and Social Stigma</h3>
        <p>Dystonia is a <strong>visible</strong> movement disorder. Studies have found that patients with dystonia were rated as less trustworthy, less attractive, and less confident compared with controls (PubMed, 2006). Social anxiety prevalence in dystonia patients is 10 times that of the general population. The severity of social anxiety is directly tied to perceived physical distortion and negative body image. Many patients begin avoiding social situations out of fear of embarrassment, leading to a cycle of avoidance, isolation, and deepening depression.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">&#128260;</div>
        <h3>Chronic Pain and the Psychological Cycle</h3>
        <p>Chronic pain in dystonia creates a vicious cycle: pain increases anxiety, anxiety increases muscle tension, and tension worsens spasms and pain. Stress activates the body's fight-or-flight response, which directly increases muscle tension. Breaking this cycle requires simultaneous physical and psychological intervention. A biopsychosocial treatment approach — combining medical care with psychological tools — offers the best results for pain management.</p>
      </div>
    </div>

    <div class="info-box warning">
      <h4>Key Finding: The Neurobiological Link</h4>
      <p>Research shows that psychiatric symptoms in dystonia often appear <strong>before</strong> the onset of motor symptoms. There is no correlation between disease severity and intensity of depression or anxiety, suggesting that psychological symptoms are part of the neurological mechanism of the disease — not merely a reaction to disability. Regardless of dystonia severity, the presence of depression and/or anxiety is among the most significant predictors of quality of life impairment.</p>
    </div>

    <h3 style="color: var(--primary); margin: 30px 0 16px;">Evidence-Based Treatment Approaches</h3>

    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <span>Cognitive Behavioral Therapy (CBT)</span>
        <span class="arrow">&#9660;</span>
      </div>
      <div class="accordion-body">
        <div class="inner">CBT has the strongest evidence base of any psychological treatment for social anxiety and depression in dystonia. Case studies show improvement in depression and anxiety lasting 6 months to 2 years after treatment. A proof-of-concept study published in 2016 (BMC Neurology) tested a combined CBT and mindfulness program in 9 dystonia patients, demonstrating improvement in measures of anxiety, depression, and general wellbeing, with effects persisting 3 months after the program ended. As of 2025, online CBT for cervical dystonia is also being evaluated. CBT is considered particularly effective for social anxiety accompanying dystonia and can be combined with pharmacotherapy as needed.</div>
      </div>
    </div>

    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <span>Mindfulness and Relaxation Techniques</span>
        <span class="arrow">&#9660;</span>
      </div>
      <div class="accordion-body">
        <div class="inner">An 8-week Mindfulness-Based Stress Reduction (MBSR) program has been shown to affect gray matter density in the amygdala, a brain region involved in the stress response. A qualitative study of 10 women with cervical dystonia found that mindfulness techniques helped increase functioning and created a sense of hope. Mind-body approaches such as yoga, mindfulness meditation, and the Feldenkrais Method are recommended as complementary approaches alongside traditional treatments. The rationale is straightforward: stress directly worsens dystonia symptoms, so relaxation techniques can reduce the amplitude of symptom fluctuations.</div>
      </div>
    </div>

    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <span>Biofeedback and Neurofeedback</span>
        <span class="arrow">&#9660;</span>
      </div>
      <div class="accordion-body">
        <div class="inner">EMG biofeedback showed 37–93% improvement in handwriting in 9 patients with writer's cramp. In an EEG neurofeedback case study for cervical dystonia, significant reduction in dystonic movements was observed and the patient learned to use diaphragmatic breathing to activate a mental state of motor control. It is important to note: the level of evidence for biofeedback in dystonia is <strong>preliminary</strong> (small samples, no large randomized controlled trials). The approach is recommended as a <strong>complementary therapy</strong> alongside other interventions. Its primary value lies in developing body awareness and a sense of agency.</div>
      </div>
    </div>

    <div class="accordion">
      <div class="accordion-header" onclick="toggleAccordion(this)">
        <span>Acceptance and Commitment Therapy (ACT)</span>
        <span class="arrow">&#9660;</span>
      </div>
      <div class="accordion-body">
        <div class="inner">ACT is a psychological approach that teaches patients to develop a new, compassionate relationship with painful thoughts and experiences rather than trying to eliminate them directly. The approach includes three main components: cognitive defusion (distancing from unhelpful thoughts), acceptance of painful experiences, and flexible attention to what truly matters. While no studies specifically on ACT in dystonia exist yet, ACT has proven effective for chronic pain and conditions where patients struggle with difficult thoughts about their body and appearance. ACT may be particularly appropriate for dystonia patients dealing with negative body image and difficulty accepting changes in their physical functioning.</div>
      </div>
    </div>

    <div class="cards-grid" style="margin-top: 40px;">
      <div class="card">
        <div class="card-icon">&#127968;</div>
        <h3>Social Isolation and Coping Strategies</h3>
        <p>A 2024 study (Psychology &amp; Health) found that social isolation and reduced social support are key mediators between stigma and psychological distress in dystonia. When people cannot work or participate in social activities, isolation deepens. Positive coping strategies include: seeking social support, reframing the meaning of illness, emotional regulation, and adopting a problem-solving approach. Gradual reengagement with social life — even in an adapted form — is encouraged. Support groups provide companionship, encouragement, and a sense of belonging.</p>
      </div>
      <div class="card green">
        <div class="card-icon">&#128106;</div>
        <h3>Impact on Family and Caregivers</h3>
        <p>A 2019 study (Journal of Neural Transmission) found that patient anxiety and number of daily caregiving hours are the primary predictors of caregiver burden in dystonia. As burden increases, caregivers may develop depressed mood and diminished quality of life. The good news: effective treatment of the patient (e.g., with botulinum toxin) also reduces caregiver burden. Psychoeducation for the family is recommended, and caregivers should be encouraged to seek their own psychological support when needed.</p>
      </div>
    </div>

    <div class="info-box success">
      <h4>The Link Between Medical Treatment and Psychological Wellbeing</h4>
      <p>Beyond physical improvement, many patients report reduced anxiety and stress following botulinum toxin or DBS treatment. However, research shows that the correlation between motor improvement and emotional wellbeing is only <strong>moderate</strong>. The implication: mental health requires independent and professional attention — it cannot be addressed solely through neurological treatment. An optimal approach integrates neurological care with ongoing professional psychological support.</p>
    </div>

    <div class="info-box">
      <h4>Finding Psychological Support</h4>
      <p>DMRF and the Dystonia Society maintain directories of mental health professionals with experience in movement disorders. Online support communities (Facebook groups, Discord servers, forums at dystonia-foundation.org) connect patients across geographic boundaries. Telehealth psychology has dramatically expanded access to mental health care for patients with mobility limitations. Your neurologist or movement disorder specialist can provide referrals to clinical psychologists familiar with chronic neurological conditions.</p>
    </div>

  </section>

  <!-- SECTION: STORIES -->
  <section class="section fade-in" id="stories">
    <div class="section-header">
      <span class="sec-icon">&#11088;</span>
      <div>
        <h2>Success Stories and Inspiration</h2>
        <p>People living with DYT1 dystonia who are changing the world</p>
      </div>
    </div>

    <div class="cards-grid">
      <div class="card">
        <div class="card-icon">&#127775;</div>
        <h3>Tyler's Hope</h3>
        <p>Tyler Seddon was diagnosed with DYT1 at age 7. His parents founded "Tyler's Hope for a Dystonia Cure," an organization that brings together leading researchers and funds cutting-edge research. The organization has become a global research engine with chapters in multiple countries and has co-funded some of the most important DYT1 studies of the past decade.</p>
        <a href="https://www.tylershope.org/" target="_blank" class="link-btn" style="margin-top:10px;">Tyler's Hope</a>
      </div>
      <div class="card green">
        <div class="card-icon">&#128161;</div>
        <h3>DBS Has Transformed Lives</h3>
        <p>Follow-up studies consistently show that DYT1 patients who underwent DBS experienced dramatic improvements in quality of life. Patients who were unable to stand or walk independently returned to independent functioning. Early surgery — before the disease becomes severely generalized — produces the best long-term outcomes, with benefits maintained for 10 or more years.</p>
      </div>
      <div class="card orange">
        <div class="card-icon">&#129309;</div>
        <h3>The International Community</h3>
        <p>The Dystonia Coalition connects 58 centers across 4 continents. Thousands of patients and families share experiences, support each other, and drive research forward. Online communities organized through DMRF and the Dystonia Society provide real-time support to patients around the world, proving that a rare diagnosis need not mean isolation.</p>
      </div>
    </div>
  </section>

  <!-- SECTION: RESOURCES -->
  <section class="section fade-in" id="resources">
    <div class="section-header">
      <span class="sec-icon">&#128279;</span>
      <div>
        <h2>Links &amp; Resources</h2>
        <p>International organizations, research databases, and key publications</p>
      </div>
    </div>

    <h3 style="color: var(--primary); margin-bottom: 16px;">International Dystonia Organizations</h3>
    <div class="cards-grid">
      <div class="card">
        <h3>DMRF</h3>
        <p>Dystonia Medical Research Foundation. The leading international organization — funds research, runs support groups and forums, and provides comprehensive patient education.</p>
        <a href="https://dystonia-foundation.org/" target="_blank" class="link-btn" style="margin-top:10px;">DMRF</a>
      </div>
      <div class="card green">
        <h3>Tyler's Hope</h3>
        <p>An organization focused specifically on DYT1, connecting leading researchers and funding targeted gene therapy and mechanistic research.</p>
        <a href="https://www.tylershope.org/" target="_blank" class="link-btn green" style="margin-top:10px;">Tyler's Hope</a>
      </div>
      <div class="card orange">
        <h3>Dystonia Europe</h3>
        <p>The European umbrella organization working to advance awareness, research, and support for dystonia patients and their families throughout Europe.</p>
        <a href="https://www.dystonia-europe.org/" target="_blank" class="link-btn orange" style="margin-top:10px;">Dystonia Europe</a>
      </div>
    </div>

    <h3 style="color: var(--primary); margin: 40px 0 16px;">Additional Dystonia Organizations</h3>
    <div style="display:flex; flex-wrap:wrap; gap:8px; margin-bottom: 30px;">
      <a href="https://www.dystonia.org.uk/" target="_blank" class="link-btn">Dystonia Society (UK)</a>
      <a href="https://dystoniacanada.org/" target="_blank" class="link-btn green">DMRF Canada</a>
      <a href="https://www.dystonia.ie/" target="_blank" class="link-btn orange">Dystonia Ireland</a>
      <a href="https://dc.rarediseasesnetwork.org/" target="_blank" class="link-btn">Dystonia Coalition</a>
    </div>

    <h3 style="color: var(--primary); margin: 40px 0 16px;">Key Research Publications</h3>
    <div class="cards-grid">
      <div class="card">
        <h3>Landmark Articles</h3>
        <ul style="list-style: none; padding: 0;">
          <li style="margin-bottom: 8px;"><a href="https://www.ncbi.nlm.nih.gov/books/NBK1492/" target="_blank" style="color:var(--primary-light);">GeneReviews: DYT-TOR1A</a> — Comprehensive and regularly updated review</li>
          <li style="margin-bottom: 8px;"><a href="https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1216929/full" target="_blank" style="color:var(--primary-light);">Frontiers 2023</a> — Updated pathogenesis and treatment review</li>
          <li style="margin-bottom: 8px;"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6745720/" target="_blank" style="color:var(--primary-light);">Neurology Genetics 2019</a> — Epidemiology of DYT1</li>
          <li style="margin-bottom: 8px;"><a href="https://www.jci.org/articles/view/139606" target="_blank" style="color:var(--primary-light);">JCI 2021</a> — Critical therapeutic window in DYT1</li>
          <li style="margin-bottom: 8px;"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7270506/" target="_blank" style="color:var(--primary-light);">Molecular Therapy 2020</a> — Allele-specific CRISPR for DYT1</li>
        </ul>
      </div>
      <div class="card green">
        <h3>Research Databases</h3>
        <ul style="list-style: none; padding: 0;">
          <li style="margin-bottom: 8px;"><a href="https://clinicaltrials.gov/search?cond=DYT1+dystonia" target="_blank" style="color:var(--primary-light);">ClinicalTrials.gov — DYT1</a></li>
          <li style="margin-bottom: 8px;"><a href="https://www.omim.org/entry/128100" target="_blank" style="color:var(--primary-light);">OMIM: DYT1 (#128100)</a></li>
          <li style="margin-bottom: 8px;"><a href="https://medlineplus.gov/genetics/gene/tor1a/" target="_blank" style="color:var(--primary-light);">MedlinePlus: TOR1A Gene</a></li>
          <li style="margin-bottom: 8px;"><a href="https://dystonia-foundation.org/focus-on-dyt1-dystonia/" target="_blank" style="color:var(--primary-light);">DMRF: Focus on DYT1</a></li>
          <li style="margin-bottom: 8px;"><a href="https://rarediseases.org/rare-diseases/early-onset-primary-dystonia/" target="_blank" style="color:var(--primary-light);">NORD: Early-Onset Primary Dystonia</a></li>
        </ul>
      </div>
    </div>
  </section>

  <!-- CAREPEDIA CTA -->
  <div class="carepedia-cta">
    <h3>Want a research-based medical information portal?</h3>
    <p>We build portals for physicians, patient associations, and medical centers. Tell us about your needs.</p>
    <a href="https://carepedia.org/#contact" class="cta-btn">Want a portal? Talk to us</a>
  </div>

  <!-- FOOTER -->
  <footer class="footer">
    <p style="margin-bottom: 16px;">
      Built by <strong>Yuval Keshtcher</strong> and his robot assistants | <a href="https://carepedia.org" style="color:var(--accent-light);text-decoration:none;">Carepedia</a>
    </p>
    <a href="https://carepedia.org/#contact" target="_blank" class="portal-request-btn" style="margin-bottom: 20px;">&#43; Want a portal for another condition?</a>
    <p style="margin-top: 20px; font-size: 15px; opacity: 0.85;">All information on this site is for educational purposes only and does not constitute a substitute for professional medical advice.</p>
    <p style="margin-top: 8px; font-size: 13px; opacity: 0.7;">
      <a href="/disclaimer" style="color:var(--accent-light);text-decoration:underline;">Legal Disclaimer</a> |
      <a href="https://wa.me/+972526414555" target="_blank" rel="noopener" style="color:var(--accent-light);text-decoration:underline;">Report an Error</a>
    </p>
    <p style="margin-top: 10px; font-size: 14px; opacity: 0.7;">Last updated: February 2026 | Includes citations from peer-reviewed literature | Psychological approach section included</p>
  </footer>

</div>

<!-- SCROLL TO TOP -->
<button class="scroll-top" id="scrollTop" onclick="window.scrollTo({top:0,behavior:'smooth'})">&#11014;</button>

<script>
function toggleMenu() {
  const sidebar = document.getElementById('sidebar');
  const toggle = document.getElementById('menuToggle');
  const overlay = document.getElementById('sidebarOverlay');
  sidebar.classList.toggle('open');
  toggle.classList.toggle('open');
  overlay.classList.toggle('active');
  toggle.textContent = sidebar.classList.contains('open') ? '\u2715' : '\u2630';
  document.body.style.overflow = sidebar.classList.contains('open') ? 'hidden' : '';
}

function closeMenu() {
  const sidebar = document.getElementById('sidebar');
  const toggle = document.getElementById('menuToggle');
  const overlay = document.getElementById('sidebarOverlay');
  sidebar.classList.remove('open');
  toggle.classList.remove('open');
  overlay.classList.remove('active');
  toggle.textContent = '\u2630';
  document.body.style.overflow = '';
}

function navigate(el) {
  document.querySelectorAll('.sidebar nav a').forEach(a => a.classList.remove('active'));
  el.classList.add('active');
  closeMenu();
}

function navigateTo(id) {
  const el = document.getElementById(id);
  if (el) el.scrollIntoView({ behavior: 'smooth' });
  document.querySelectorAll('.sidebar nav a').forEach(a => {
    a.classList.toggle('active', a.getAttribute('href') === '#' + id);
  });
}

function toggleAccordion(header) {
  const body = header.nextElementSibling;
  const isOpen = header.classList.contains('open');
  header.classList.toggle('open');
  body.style.maxHeight = isOpen ? '0' : body.scrollHeight + 'px';
}

function switchTab(tabGroup, tabName) {
  document.querySelectorAll('[data-tab-group="' + tabGroup + '"] .tab-btn').forEach(b => {
    b.classList.toggle('active', b.dataset.tab === tabName);
  });
  document.querySelectorAll('[data-tab-content="' + tabGroup + '"]').forEach(c => {
    c.classList.toggle('active', c.dataset.tab === tabName);
  });
}

// Scroll progress bar
window.addEventListener('scroll', () => {
  const scrollTop = document.getElementById('scrollTop');
  const progressBar = document.getElementById('progressBar');
  const scrolled = window.scrollY;
  const maxScroll = document.documentElement.scrollHeight - window.innerHeight;
  const pct = maxScroll > 0 ? (scrolled / maxScroll) * 100 : 0;
  progressBar.style.width = pct + '%';
  scrollTop.classList.toggle('visible', scrolled > 500);

  // Scroll spy
  const sections = document.querySelectorAll('.section[id], .hero[id]');
  let current = '';
  sections.forEach(s => {
    if (scrolled >= s.offsetTop - 100) current = s.id;
  });
  if (current) {
    document.querySelectorAll('.sidebar nav a').forEach(a => {
      a.classList.toggle('active', a.getAttribute('href') === '#' + current);
    });
  }
});

// Fade-in on scroll (IntersectionObserver)
const fadeEls = document.querySelectorAll('.fade-in');
const observer = new IntersectionObserver((entries) => {
  entries.forEach(entry => {
    if (entry.isIntersecting) {
      entry.target.classList.add('visible');
    }
  });
}, { threshold: 0.1, rootMargin: '0px 0px -50px 0px' });
fadeEls.forEach(el => observer.observe(el));

// Portal search — with highlight, clear button, and debounce
let searchTimeout;
function searchPortal(query) {
  clearTimeout(searchTimeout);
  searchTimeout = setTimeout(() => _doSearch(query), 150);
}

function _doSearch(query) {
  const resultsDiv = document.getElementById('searchResults');
  const clearBtn = document.getElementById('searchClear');

  clearBtn.style.display = query && query.length > 0 ? 'block' : 'none';

  if (!query || query.length < 2) {
    resultsDiv.style.display = 'none';
    document.querySelectorAll('.section').forEach(s => {
      s.style.display = '';
    });
    return;
  }
  const q = query.toLowerCase();
  const sections = document.querySelectorAll('.section[id]');
  const matches = [];
  sections.forEach(s => {
    const text = s.textContent.toLowerCase();
    const title = s.querySelector('h2') ? s.querySelector('h2').textContent : '';
    const subtitle = s.querySelector('.section-header p') ? s.querySelector('.section-header p').textContent : '';
    if (text.includes(q)) {
      const count = (text.match(new RegExp(q.replace(/[.*+?^${}()|[\]\\]/g, '\\$&'), 'g')) || []).length;
      matches.push({ id: s.id, title: title, subtitle: subtitle, count: count, el: s });
      s.style.display = '';
    } else {
      s.style.display = 'none';
    }
  });
  matches.sort((a, b) => b.count - a.count);

  if (matches.length > 0 && matches.length < sections.length) {
    resultsDiv.innerHTML = '<div style="background:var(--card);border-radius:var(--radius);padding:16px 20px;box-shadow:var(--shadow);">' +
      '<p style="font-size:14px;color:var(--text-light);margin-bottom:8px;">' + matches.length + ' result(s) found:</p>' +
      matches.map(m =>
        '<a href="#' + m.id + '" onclick="navigateTo(\'' + m.id + '\')" style="display:block;padding:10px 12px;color:var(--primary);text-decoration:none;border-radius:8px;font-weight:600;transition:var(--transition);">' +
        m.title +
        (m.count > 1 ? ' <span style="font-size:12px;color:var(--text-light);font-weight:400;">(' + m.count + ' mentions)</span>' : '') +
        '</a>'
      ).join('') +
      '</div>';
    resultsDiv.style.display = 'block';
  } else if (matches.length === sections.length) {
    resultsDiv.style.display = 'none';
  } else {
    resultsDiv.innerHTML = '<div style="background:var(--card);border-radius:var(--radius);padding:16px 20px;box-shadow:var(--shadow);"><p style="font-size:14px;color:var(--text-light);">No results found. Try a different term.</p></div>';
    resultsDiv.style.display = 'block';
  }
}

function clearSearch() {
  const input = document.getElementById('portalSearch');
  input.value = '';
  input.focus();
  searchPortal('');
}
</script>

</body>
</html>
